Tizona com­pletes spin­out of can­cer pro­gram as part of Gilead buy­out; Dyne files for $100M IPO

Tizona has com­plet­ed the spin­out of a new com­pa­ny that will fo­cus on de­vel­op­ing its now-for­mer lead pro­gram in­volv­ing an an­ti-CD39 an­ti­body.

The new com­pa­ny, Tr­ishu­la Ther­a­peu­tics, is de­signed to fur­ther progress and fo­cus on the ex­ist­ing TTX-030 col­lab­o­ra­tion that Tizona had signed with Ab­b­Vie back in ear­ly 2019. Cur­rent­ly, the can­di­date is be­ing stud­ied in Phase I/Ib tri­als, both by it­self and in com­bi­na­tion with an an­ti-PD-1 agent and stan­dard chemother­a­py, in adults with ad­vanced can­cers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER